Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prodrugs of a 1′-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV
Richard L. Mackman, Hon C. Hui, Michel Perron, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 8, pp. 5001-5017
Closed Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms
Laura J. Stevens, Andrea J. Pruijssers, Hery W. Lee, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 656
Open Access | Times Cited: 189
Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
Robert M. Cox, Josef D. Wolf, Carolin M. Lieber, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 98
Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice
Alexandra Schäfer, David R. Martinez, John J. Won, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 643
Open Access | Times Cited: 70
Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants
Jared Pitts, Jiani Li, Jason K. Perry, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 6
Open Access | Times Cited: 64
Oral GS-441524 derivatives: Next-generation inhibitors of SARS‐CoV‐2 RNA‐dependent RNA polymerase
Zhonglei Wang, Liyan Yang, Xian-qing Song
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 48
Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro
Sheli R. Radoshitzky, Patrick L. Iversen, Xianghan Lu, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 35
Preparing for the next viral threat with broad-spectrum antivirals
Marwah Karim, Chieh‐Wen Lo, Shirit Einav
Journal of Clinical Investigation (2023) Vol. 133, Iss. 11
Open Access | Times Cited: 31
Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys
Richard L. Mackman, Rao Kalla, Darius Babusis, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 11701-11717
Open Access | Times Cited: 31
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 10
A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents
Thuc Nguyen Dan, Kim Donckers, Laura Vangeel, et al.
Antiviral Research (2021) Vol. 192, pp. 105122-105122
Open Access | Times Cited: 56
Broad‐spectrum prodrugs with anti‐SARS‐CoV‐2 activities: Strategies, benefits, and challenges
Zhonglei Wang, Liyan Yang
Journal of Medical Virology (2021) Vol. 94, Iss. 4, pp. 1373-1390
Closed Access | Times Cited: 43
Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2
Richard L. Mackman
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 3, pp. 338-347
Open Access | Times Cited: 33
The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants
Liu Cao, Yingjun Li, Sidi Yang, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 661
Open Access | Times Cited: 32
Recent Progress toward the Discovery of Small Molecules as Novel Anti-Respiratory Syncytial Virus Agents
Tommaso Felicetti, Chiara Sarnari, Roberta Gaito, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 8
Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection
Meghan S. Vermillion, Eisuke Murakami, Bin Ma, et al.
Science Translational Medicine (2021) Vol. 14, Iss. 633
Open Access | Times Cited: 40
Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19
Tomáš Cihlář, Richard L. Mackman
Antiviral Therapy (2022) Vol. 27, Iss. 2, pp. 135965352210827-135965352210827
Open Access | Times Cited: 25
Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model
Ruxue Zhang, Yumin Zhang, Wei Zheng, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 25
An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges
Xiao‐Ying Xu, Yuheng Chen, Xinyu Lu, et al.
Biochemical Pharmacology (2022) Vol. 205, pp. 115279-115279
Open Access | Times Cited: 24
Broad-Spectrum In Vitro Antiviral Activity of ODBG-P-RVn: An Orally-Available, Lipid-Modified Monophosphate Prodrug of Remdesivir Parent Nucleoside (GS-441524)
Michael K. Lo, Punya Shrivastava-Ranjan, Payel Chatterjee, et al.
Microbiology Spectrum (2021) Vol. 9, Iss. 3
Open Access | Times Cited: 31
Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola
Victoria C. Yan, Florian L. Müller
Antimicrobial Agents and Chemotherapy (2021) Vol. 65, Iss. 10
Open Access | Times Cited: 30
Remdesivir treatment does not reduce viral titers in patients with COVID-19
Isa Faghihi, Victoria C. Yan
Antimicrobial Agents and Chemotherapy (2024) Vol. 68, Iss. 8
Closed Access | Times Cited: 4
Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants
Lauren Rodriguez, J. Lizbeth Reyes Zamora, Dong Han, et al.
Viruses (2025) Vol. 17, Iss. 2, pp. 168-168
Open Access
The Combination of GS-441524 (Remdesivir) and Ribavirin Results in a Potent Antiviral Effect Against Human Parainfluenza Virus 3 Infection in Human Airway Epithelial Cell Cultures and in a Mouse Infection Model
Yuxia Lin, Birgit Weynand, Xin Zhang, et al.
Viruses (2025) Vol. 17, Iss. 2, pp. 172-172
Open Access
Current Antiviral Therapies and Promising Drug Candidates against Respiratory Syncytial Virus Infection
Ziheng Feng, Zhengde Xie, Lili Xu
Virologica Sinica (2025)
Open Access
ISAR opinion: Product development partnerships to fund pandemic antiviral research
Luis M. Schang
Antiviral Research (2025) Vol. 238, pp. 106166-106166
Closed Access
Page 1 - Next Page

Scroll to top